Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?

Aquestive Therapeutics (AQST) shares surged 14.8% on notable volume, driven by investor optimism surrounding the potential FDA approval of its key product candidate, Anaphylm, for severe allergic reactions. The FDA's decision to waive the advisory committee meeting indicates a lower perceived risk for the treatment, with a final decision anticipated by January 31, 2026. This positive market reaction is further supported by a significant 24.4% upward revision in the consensus EPS estimate for the upcoming quarter.

Analysis

Aquestive Therapeutics (AQST) experienced a significant 14.8% share price increase to $5.67 on heightened trading volume, extending its four-week gain to 26.3%. This rally is primarily driven by investor optimism surrounding the regulatory path for its key product candidate, Anaphylm. A critical positive signal was the FDA's decision to waive an advisory committee meeting for the drug's application, which is interpreted as an indication of a lower perceived risk profile ahead of a final decision expected by January 31, 2026. While the stock's momentum is strong, the company's near-term fundamentals appear weak, with upcoming quarterly revenues projected to decline 1.3% to $13.36 million and earnings expected to be a flat year-over-year loss of $0.13 per share. However, a powerful counter-indicator is the 24.4% upward revision in the consensus EPS estimate over the past 30 days, a trend that empirical research correlates with near-term price appreciation and suggests underlying sentiment may be stronger than headline financials indicate.

Key Decisions for Investors

• Investors should view AQST primarily as a catalyst-driven investment, where the potential long-term value from the FDA's decision on Anaphylm is currently outweighing its weak near-term revenue and earnings projections.
• The significant 24.4% upward revision in EPS estimates is a key bullish indicator to monitor, as continued positive revisions could signal further near-term stock appreciation independent of the upcoming quarterly results.
• Given the final FDA decision is not until early 2026, positions in AQST require a long-term perspective and an acceptance of volatility, as the current Zacks Rank of 'Hold' reflects the existing tension between regulatory optimism and fundamental performance.